

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 February 2023 (16.02.2023)



(10) International Publication Number
WO 2023/019200 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) A61P 37/06 (2006.01)
A61K 31/00 (2006.01) C07K 16/28 (2006.01)

(21) International Application Number:

PCT/US2022/074830

(22) International Filing Date:

11 August 2022 (11.08.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/232,131 11 August 2021 (11.08.2021) US
63/285,297 02 December 2021 (02.12.2021) US

(71) Applicant: **VIELA BIO, INC.** [US/US]; One MedImmune Way, Gaithersburg, Maryland 20878 (US).

(72) Inventors; and

(71) Applicants: **DRAPPA, Jorn**; c/o Viela Bio, Inc., One MedImmune Way, Gaithersburg, Maryland 20878 (US). **KATZ, Eliezer**; c/o Viela Bio, Inc., One MedImmune Way, Gaithersburg, Maryland 20878 (US). **CIMBORA, Daniel**; c/o Viela Bio, Inc., One MedImmune Way, Gaithersburg,

Maryland 20878 (US). **FALLOON, Judith**; c/o Viela Bio, Inc., One MedImmune Way, Taithertburg, Maryland 20878 (US).

(74) Agent: **BROWN, Fraser et al.**; COOLEY LLP, 1299 Pennsylvania Avenue NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: INEBILIZUMAB AND METHODS OF USING THE SAME IN THE TREATMENT OR PREVENTION OF IGG4-RELATED DISEASE




FIG. 1

(57) Abstract: Provided herein are compositions and methods comprising anti-CD19 binding agents and methods of using the same for the treatment or amelioration of Immunoglobulin G4-related disease (IgG4-RD). Also provided are compositions and methods of using Inebilizumab for the treatment or amelioration of IgG4-RD and IgG4-RD flare.

[Continued on next page]

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*